期刊文献+

丹栀逍遥散合二至丸治疗三苯氧胺不良反应的研究 被引量:18

Clinical Study of Dan Zhi Xiao Yao San and Er Zhi Wan Jia Jian in Treating the Hormone Therapy of Breast Cancer the Clinical Observation of after Menopause Syndrome
暂未订购
导出
摘要 目的:观察丹栀逍遥散合二至丸加减对乳腺癌患者三苯氧胺(TAM)内分泌治疗不良反应的治疗作用。方法:将64例符合入选标准的乳腺癌患者,随机分为治疗组和对照组。治疗组:TAM,每次10 mg,每日2次,温开水送服,同时配合丹栀逍遥散合二至丸加减浓煎300 mL,日1剂,早、晚各服1次。对照组:TAM,每次10 mg,每日2次,温开水送服。治疗2月后评价疗效,比较两组患者库坡曼(kuppermann)症状积分、药物不良反应等观察指标。结果:治疗组kuppermann症状积分明显低于治疗前(P<0.05),临床缓解率(显效+有效)达90.63%;对照组积分较前无改善。两组缓解率比较,差异有统计学意义(P<0.01)。结论:应用TAM配合丹栀逍遥散合二至丸加减治疗乳腺癌,能够改善潮热汗出、失眠、疲乏及情绪异常等内分泌治疗后不良反应,提高生活质量。 Objective:To observe the therapeutical effect of Dan Zhi Xiao Yao San with Er Zhi Wan Jia Jian on adverse reactions of breast cancer of endocrine therapy on tamoxifen(TAM).Methods:64 patients with breast cancer according to the criteria,randomly divided into the treatment group and control group.The treatment group:TAM,every time 10 mg,2 times a day with lukewarm water service,at the same time cooperating with 300ml fried Dan Zhi Xiao Yao San with Er Zhi Wan Jia Jian,day 1 agent,the morning and evening take 1 times.Control group:TAM,every time 10 mg,2 times a day with lukewarm water service.Evaluate the efficacy after 2 months.Compared the kuppermann symptom scores,adverse drug reaction and other outcome of two groups of patients.Results:The kuppermann symptom scores of treatment group is significantly lower than no treatment(P0.05),clinical response rate(powerfully+effective) 90.63%;the control group did not improve the previous points.The remission rate of two groups was significant difference(P0.01).Conclusion:The application of TAM with Dan Zhi Xiao Yao San with Er Zhi Wan Jia Jian to treat breast cancer,can improve the endocrine therapy adverse reaction such as hot flashes sweating,insomnia,fatigue,and mood disorders.So that we can improve the quality of life.
机构地区 河南中医学院
出处 《中医学报》 CAS 2012年第1期6-8,共3页 Acta Chinese Medicine
基金 国家中医药管理局科技攻关项目(编号:0203JP25)
关键词 丹栀逍遥散 二至丸 乳腺癌 内分泌 更年期综合征 不良反应 Dan Zhi Xiao Yao San Er Zhi Wan breast cancer endocrine therapy menopause syndrome adverse reaction
  • 相关文献

参考文献5

二级参考文献22

  • 1张少华,江泽飞,宋三泰,申戈,王涛,曾敏,郭中宁.泰索帝联合希罗达治疗蒽环类化疗失败复发转移性乳腺癌的临床研究[J].癌症进展,2004,2(3):217-220. 被引量:59
  • 2王涛,江泽飞,宋三泰,张少华,申戈,于静新.单药希罗达治疗复发转移性乳腺癌的疗效观察[J].中华肿瘤杂志,2004,26(6):379-381. 被引量:57
  • 3张保宁,王仲照.国际乳腺癌研究新进展——第28届圣安东尼奥乳腺癌学术研讨会报道[J].中华医学杂志,2006,86(8):573-576. 被引量:13
  • 4Marian J.E.,Mounts MD,Elisabeth G.E,Tamoxifen treatment and gynecologic side effects:A review [J].Obstetrics & Gynecology,2001,97:855.
  • 5Morgan MA,Gincherman y,Mikuta JJ,Endometriosis and tamoxifen therapy[J].Invest,1998,45:126.
  • 6Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B- 28[J]. J Clin Oncol, 2005, 23(16): 3 686-3 696.
  • 7Boer K, Lang I, Juhos E, et al. Adjuvant therapy of breast cancer with docetaxel - containing combination (TAC) [ J ]. Pathol Oncol Res, 2003, 9(3): 166- 169.
  • 8Early Breast Cancer Trialists' Colhhorative Group. Tamoxifen for early breast cancer: An overview of the randomized trials[J]. Lancet, 1998, 351(9 114): 1 451 - 1 467.
  • 9The ATAC trialist group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial [ J ]. Lancet, 2002, 359 (9 324 ) : 2 131-2 139.
  • 10Goes PE, Lngle JM, Martion S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for earlystage breast cancer[J]. N Engl J Med, 2003, 349(19): 1 793-1 802.

共引文献65

同被引文献210

引证文献18

二级引证文献158

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部